Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Clinical trial NCT07336732 · RECRUITING

Trial details

NCT number: NCT07336732
Sponsor: Avistone Biotechnology Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small-Cell Lung Cancer

Start date: 2026-03-11
Primary completion: 2026-11-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.